Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$328.42 USD

328.42
200,439

+13.65 (4.34%)

Updated Nov 5, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Here's Why West Pharmaceutical Services (WST) is a Great Momentum Stock to Buy

Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.

BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.

Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates

Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.

Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up

Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow

Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected

Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.

Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up

Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.

Cardinal Health (CAH) Q4 Earnings Lag, Revenues Top Estimates

Although Cardinal Health (CAH) witnessed margin contraction in its fiscal fourth-quarter results, rise in revenues in both its segments is encouraging.

DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) second-quarter results benefit from strong segmental performance.

Change Healthcare (CHNG) Q1 Earnings Miss, Revenues Beat

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q1

McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.

DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.

PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top

PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.

CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up

CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.

Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Earnings Estimates Rising for West Pharmaceutical (WST): Will It Gain?

West Pharmaceutical (WST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand

Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.

Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.

Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up

Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.

Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up

Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.

Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.